Statement: the primary trial is not testing a novel Physiotherapy or radiotherapy intervention.
Primary_evidence: INTERVENTION 1:    Akt Inhibitor MK-2206   Akt Inhibitor MK-2206 orally once a week on days 1, 8, 15, and 22. Starting dose 200 mg, courses repeat every 28 days.